This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. MapLight Therapeutics on Monday advanced plans to go public with the help of a little-used regulatory workaround that would allow it to price a new stock offering during a federal government shutdown. The biotechnology company, which is developing drugs for neurological diseases, said in a statement that it plans to sell 14,750,000 shares at $17 apiece in a com ...